ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer
SHANGHAI, Oct. 19, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical data on its Nectin-4-targeting antibody-drug conjugate (ADC)...